Medullary thyroid cancer screening

Medullary thyroid cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Medullary thyroid cancer from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
CT
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Medullary thyroid cancer screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Medullary thyroid cancer screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Medullary thyroid cancer screening
CDC on Medullary thyroid cancer screening
Medullary thyroid cancer screening in the news
Blogs on Medullary thyroid cancer screening
Directions to Hospitals Treating Medullary thyroid cancer
Risk calculators and risk factors for Medullary thyroid cancer screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

According to the American Society of Clinical Oncology, screening for medullary thyroid cancer by RET gene testing is recommended for children with increased risk of medullary thyroid cancer.

Screening

Screening for medullary thyroid cancer The DNA-based testing of the c-RET gene ▸ Children with c-RET codon 609, 768, 790, 791, 804 and 891 mutations are more prone to less aggressive and slowly growing medullary thyroid cancer and a periodic pentagastrin-stimulated test with thyroidectomy, at the first abnormal test result, has been recommended. ▸ Individuals with c-RET codon 609, 611, 618, 620, 630, 634, 790, V804L, 883, 918 or 922 mutations should be routinely screened for pheochromocytoma by annual determinations of fractionated urinary and free plasma metanephrines and catecholamines. Adapted from Marquard J, Eng C. Multiple Endocrine Neoplasia Type 2. 1999 Sep 27 [Updated 2015 Jun 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1257/ Reference